ロード中...
ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
Backgrounds & purpose: Prognosis of patients with primary central nervous system lymphoma (PCNSL) remains poor despite multiagent immunochemotherapy, and standard of care for relapsed or refractory (r/r) PCNSL has not been established. Recent progresses on molecular genetics and biology of PCNSL...
保存先:
| 出版年: | Neurooncol Adv |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7699110/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.078 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|